Loading…
RedHill Biopharma Ltd. is projected to rise to $1.09 by 2027, a +8% move from its current price of $1.01. RDHL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.9767 | $1.01 | $1.05 | +0.05% |
| May 30 | $0.9635 | $1.01 | $1.06 | +0.10% |
| May 31 | $0.9536 | $1.01 | $1.07 | +0.15% |
| Jun 1 | $0.9455 | $1.01 | $1.08 | +0.20% |
| Jun 2 | $0.9384 | $1.01 | $1.09 | +0.25% |
| Jun 3 | $0.932 | $1.01 | $1.10 | +0.29% |
| Jun 4 | $0.9263 | $1.01 | $1.11 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9263 | $1.01 | $1.11 | +0.34% |
| Week 2 | $0.8955 | $1.02 | $1.15 | +0.69% |
| Week 3 | $0.8732 | $1.02 | $1.19 | +1.03% |
| Week 4 | $0.8553 | $1.02 | $1.23 | +1.38% |
| Week 5 | $0.8402 | $1.03 | $1.26 | +1.73% |
| Week 6 | $0.8271 | $1.03 | $1.29 | +2.08% |
| Week 7 | $0.8154 | $1.03 | $1.31 | +2.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. It develops and commercializes Talicia for the treatment of H. pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults.
Its pipeline consists of five therapeutic candidates in clinical development, including opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
RDHL is trading at $0.9798 per share. The current price is reflected in a market with a market cap of $5.09M and a rank of 5336. The 2026 forecast shows an average price of $0.9798 with a range from $0.745 to $1.29 and neutral sentiment, indicating near-term stability around the current price.
From 2027 onward the forecast envisions bullish momentum, with the average price rising to $1.07 in 2027 and $1.31 in 2028, and continued upside through 2030 ($1.24), 2040 ($2.32), and 2050 ($3.11). The maximum values in these years suggest notable upside, such as $1.91 in 2030, $4.28 in 2040, and $6.38 in 2050.
A major floor 35.0% below — a decisive break under it would weaken the trend.
The nearest floor, 22.3% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 34.7% above — clearing it would confirm fresh momentum.
Key RDHL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RDHL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9708 | Buy | $0.9869 | Buy |
| MA 10 | $0.9756 | Buy | $0.9832 | Buy |
| MA 20 | $1.01 | Buy | $0.9774 | Buy |
| MA 50 | $0.9113 | Buy | $0.9626 | Buy |
| MA 100 | $1.01 | Buy | $1.03 | Sell |
| MA 200 | $1.20 | Sell | $1.78 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.61 | Neutral |
| Stoch RSI (14) | 69.61 | Neutral |
| CCI (20) | 7.52 | Neutral |
| Williams %R (14) | -18.02 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 0.00 | Neutral |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 81.98 | Sell |
| TRIX (15) | 0.35 | Buy |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 48.95 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 1.00 | Buy |
| ADX (14) | 19.40 | Neutral |
| ATR (14) | 0.02 | Info |
The near-term technical picture is neutral. The RSI(14) is 50, and the 50-day simple moving average sits at $0.9054 while the 200-day simple moving average is $1.21. The stock faces a nearby resistance at $1.09 and a support level at $0.785.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.745 | $1.01 | $1.34 | 0% | Neutral | |
| $0.8417 | $1.09 | $1.50 | +8% | Neutral | |
| $0.9896 | $1.32 | $1.90 | +31% | Bullish | |
| $1.04 | $1.44 | $2.14 | +42% | Bullish | |
| $0.8922 | $1.26 | $1.93 | +25% | Bullish | |
| $0.8676 | $1.26 | $1.97 | +24% | Bullish | |
| $0.88 | $1.30 | $2.09 | +29% | Bullish | |
| $0.8837 | $1.34 | $2.19 | +32% | Bullish | |
| $1.11 | $1.71 | $2.86 | +70% | Bullish | |
| $1.11 | $1.74 | $2.96 | +73% | Bullish | |
| $1.35 | $2.32 | $4.23 | +130% | Bullish | |
| $1.58 | $3.21 | $6.47 | +217% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.745 | $1.01 | $1.18 | +0.00% |
| June 2026 | $0.8442 | $0.9967 | $1.21 | -1.32% |
| July 2026 | $0.8851 | $1.06 | $1.30 | +5.96% |
| August 2026 | $0.9052 | $1.09 | $1.36 | +3.12% |
| September 2026 | $0.8717 | $1.06 | $1.33 | -3.04% |
| October 2026 | $0.8629 | $1.05 | $1.34 | -0.38% |
| November 2026 | $0.8778 | $1.08 | $1.38 | +2.29% |
| December 2026 | $0.8403 | $1.04 | $1.34 | -3.76% |
Click any year to see its month-by-month RDHL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
RedHill Biopharma Ltd.'s 2026 outlook centres on $1.01, within a $0.745 to $1.34 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, RDHL could reach as high as $1.50, with a base case around $1.09 and support toward $0.8417 — roughly +8% from $1.01. Price action looks broadly range-bound.
Expect RDHL to range from $0.9896 to $1.90 through 2028. The $1.32 average target implies a +31% move from current prices. That is up +22% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The RDHL price prediction for 2029 points to an average of $1.44 (low $1.04, high $2.14) — a potential gain of +42% on today's $1.01. Momentum favours further upside here.
In 2030, RDHL is projected to trade between $0.8922 and $1.93, averaging $1.26 — a potential gain of +25% from today's $1.01. That is -12% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
RedHill Biopharma Ltd.'s 2031 outlook centres on $1.26, within a $0.8676 to $1.97 range. That is 0% versus the projected 2030 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2032, RDHL could reach as high as $2.09, with a base case around $1.30 and support toward $0.88 — roughly +29% from $1.01. Buyers look set to stay in control over this stretch.
Expect RDHL to range from $0.8837 to $2.19 through 2033. The $1.34 average target implies a +32% move from current prices. That is up +3% on the projected 2032 average. Momentum favours further upside here.
The RDHL price prediction for 2034 points to an average of $1.71 (low $1.11, high $2.86) — a potential gain of +70% on today's $1.01. Buyers look set to stay in control over this stretch.
In 2035, RDHL is projected to trade between $1.11 and $2.96, averaging $1.74 — a potential gain of +73% from today's $1.01. That is up +2% on the projected 2034 average. Momentum favours further upside here.
RedHill Biopharma Ltd.'s 2040 outlook centres on $2.32, within a $1.35 to $4.23 range. That is up +33% on the projected 2035 average. That marks a +130% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, RDHL could reach as high as $6.47, with a base case around $3.21 and support toward $1.58 — roughly +217% from $1.01. Momentum favours further upside here.
Investing $1,000 in RDHL today (≈ 990.09901 RDHL) could be worth
$3,173.76
+$2,173.76 (+217%) by 2050 · US Dollar
Based on the average projected RDHL price of $3.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RDHLwould be worth at today's price.
$1,000 invested in RDHL on May 27, 2025 (≈ 543.478251 RDHL) would be worth
$548.91
-$451.09 (-45.1%) today · 0.55× · US Dollar
Based on a RDHL entry price of $1.84 vs. today's $1.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.919 | $1,099.02 | +9.9% |
| 1 month ago | $1.03 | $980.58 | -1.9% |
| 3 months ago | $0.98 | $1,030.61 | +3.1% |
| 6 months ago | $1.2 | $841.67 | -15.8% |
| 1 year ago | $1.84 | $548.91 | -45.1% |
| All time (5.0y) ago | $7,290 | $0.14 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RDHL forecast.
Our base-case forecast reaches $2.00 around 2040.
Implied market cap at $2.00: $10.38M
The multi-year forecast shows a bullish trajectory for RDHL, with higher average prices in future years. In 2030 the forecast shows an average price of $1.24 with a max of $1.91 and a min of $0.8655, for a 26.1% ROI and bullish sentiment. By 2040 the average is projected at $2.32 with a max of $4.28 (ROI 136.4%), and by 2050 the average could reach $3.11 with a max of $6.38 (ROI 217.2%), also bullish.
Earlier years show a progression from neutral in 2026 (avg $0.9798, ROI 0%, neutral) to positive momentum in 2027–2029 (e.g., 2027 ROI 9.3%, 2028 ROI 33.5%, 2029 ROI 43.3%). These figures illustrate a potential upside path, but they are estimates, not guarantees, and carry the risks associated with high volatility (annualized volatility 70%).
Tap a question to reveal the answer.
RDHL is $0.9798 per share. The market cap is $5.09M and the rank is 5336.
Avg $1.24, max $1.91, min $0.8655; ROI 26.1%; sentiment BULLISH.
Yes. The forecast max shows $2.11 in 2029, with higher max values of $2.86 (2034), $2.94 (2035), $4.28 (2040), and $6.38 (2050).
RSI(14) is 50. SMA(50) is $0.9054. SMA(200) is $1.21. Support is $0.785 and resistance is $1.09. The 30-day range is $0.7761 to $1.24 and annualized volatility is 70%.
The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
RedHill Biopharma Ltd. Community Discussion
0Share your RedHill Biopharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.